Literature DB >> 7834802

Aflatoxin B1-induced immortalization of cultured skin fibroblasts from a patient with Li-Fraumeni syndrome.

T Tsutsui1, T Fujino, S Kodama, M A Tainsky, J Boyd, J C Barrett.   

Abstract

To examine the mechanisms of immortalization in human cells, normal human diploid fibroblasts (WHE-7) and skin fibroblasts from a patient with Li-Fraumeni syndrome (MDAH 087) and a mutant p53 allele were treated with aflatoxin B1 (AFB1). Exogenous metabolic activation of AFB1 with rat liver post-mitochondrial supernatant (PMS) was used and the optimal treatment conditions needed were determined by the inducibility of unscheduled DNA synthesis. The same degree of cytotoxicity was observed with MDAH 087 cells and normal WHE-7 cells treated with AFB1 at 0.1, 0.3 or 1 microgram/ml for 2 h with a 2% PMS mixture. All WHE-7 cell cultures (AFB1-treated and controls) failed to escape from senescence, whereas three out of nine AFB1-treated cultures of MDAH 087 cells escaped senescence. MDAH 087 cells treated with 0.1 microgram/ml of AFB1 two or three times initially decreased in growth approximately 40 days [10 population doublings (PD)] after the first treatment. However, the cells recovered with faster growth rates after approximately 100 additional days and grew continuously. Both cultures were immortal, defined as continuous growth for over 300 PD. Cells treated once with 0.3 microgram/ml of AFB1 also escaped senescence, although they had about a 230 day time lag before restoration of cell growth. The three AFB1-treated cell lines exhibited altered morphologies, chromosome aberrations (numerical and structural aberrations) and loss of the wild-type p53 allele. Although immortal, the cells were non-tumorigenic in nude mice. Spontaneous immortalization of untreated MDAH 087 was not observed in this study. The results indicate that AFB1 treatment of cells from a Li-Fraumeni patient, but not cells from normal individuals, can induce immortalization. This model may be useful for studying mechanisms of chemically induced immortalization.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7834802     DOI: 10.1093/carcin/16.1.25

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

Review 1.  Genotype phenotype correlation in Li-Fraumeni syndrome kindreds and its implications for management.

Authors:  R N Moule; S G Jhavar; R A Eeles
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

Review 2.  Tumour predisposition and cancer syndromes as models to study gene-environment interactions.

Authors:  Michele Carbone; Sarah T Arron; Bruce Beutler; Angela Bononi; Webster Cavenee; James E Cleaver; Carlo M Croce; Alan D'Andrea; William D Foulkes; Giovanni Gaudino; Joanna L Groden; Elizabeth P Henske; Ian D Hickson; Paul M Hwang; Richard D Kolodner; Tak W Mak; David Malkin; Raymond J Monnat; Flavia Novelli; Harvey I Pass; John H Petrini; Laura S Schmidt; Haining Yang
Journal:  Nat Rev Cancer       Date:  2020-05-29       Impact factor: 60.716

Review 3.  Li-Fraumeni syndrome--a molecular and clinical review.

Authors:  J M Varley; D G Evans; J M Birch
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Immortalization of normal human gingival keratinocytes and cytological and cytogenetic characterization of the cells.

Authors:  Chikahiro Kubo; Takeo W Tsutsui; Yukiko Tamura; Shin-Ichi Kumakura; Takeki Tsutsui
Journal:  Odontology       Date:  2009-01-29       Impact factor: 2.634

Review 5.  Critical pathways in cellular senescence and immortalization revealed by gene expression profiling.

Authors:  A L Fridman; M A Tainsky
Journal:  Oncogene       Date:  2008-08-18       Impact factor: 9.867

6.  Spontaneous immortalization of mouse liver sinusoidal endothelial cells.

Authors:  Xiuhua Zhao; Qian Zhao; Zhen Luo; Yan Yu; Na Xiao; Xuan Sun; Lamei Cheng
Journal:  Int J Mol Med       Date:  2015-01-13       Impact factor: 4.101

7.  Chromosome instability is a predominant trait of fibroblasts from Li-Fraumeni families.

Authors:  J M Boyle; E L Mitchell; M J Greaves; S A Roberts; K Tricker; E Burt; J M Varley; J M Birch; D Scott
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.